/
INSM
$123.93-$2.40 (-1.90%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$28.9B
218M shares
52-week range
$90.39 – $212.75
27% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$101.04
Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
www.insmed.com- Employees
- 1,664
- IPO / List date
- Jun 1, 2000
- HQ
- BRIDGEWATER, NJ
Held by traders on TradeandTell
No one on the platform currently holds INSM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 295,579 | $48.3M |
| Renaissance Technologiesas of 2026-03-31 | 20,300 | $3.3M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2011-03-03 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded INSM yet.
